Emmanuel Normant, Vice President of Preclinical Sciences at TG Therapeutics shares why he thinks the CD47/SIRPa pathway is so interesting, discusses what conversations need to happen now to help advance this field and more in this exclusive interview.  

Click here to download your copy.

 

Leave a Reply